<DOC>
	<DOCNO>NCT00254254</DOCNO>
	<brief_summary>This study first evaluation exenatide adolescent subject type 2 diabetes mellitus design evaluate blood level drug ( pharmacokinetics ) , drug 's biochemical physiological effect ( pharmacodynamics ) , tolerability exenatide subject .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics , Pharmacodynamics , Tolerability Exenatide Adolescent Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Treatment diet exercise alone stable dose metformin , sulfonylurea , metformin plus sulfonylurea least 3 month . Has HbA1c 6.0 % 11.0 % , inclusive , screen . Has body weight &gt; = 50 kg screening . Received investigational drug participate type clinical trial within 3 month prior screen . Currently participate interventional study . Is currently treat follow excluded medication : Sulfonylurea chlorpropamide Thiazolidinedione within 3 month screen . Î‘lpha glucosidase inhibitor within 3 month screen . Meglitinide within 3 month screen . Insulin within 3 month screen . Pramlintide within 3 month screen .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>adolescent</keyword>
	<keyword>exenatide</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>